🚀 VC round data is live in beta, check it out!
Asterasys Valuation Multiples
Discover revenue and EBITDA valuation multiples for Asterasys and similar public comparables like Carlsmed, CapsoVision, TriSalus Life Sciences, Soracom and more.
Asterasys Overview
About Asterasys
Asterasys Co Ltd is a professional healthcare and biomedical corporation based in Korea. It is engaged in the Manufacture of electro-diagnostic and electro-therapeutic apparatuses featuring body composition analyzers such as the InBalance series and HIFU systems such as the Liftera series, it provides total solutions with healthcare, skincare, and IoT-oriented services that can connect with its product portfolio.
Founded
2015
HQ
Employees
N/A
Website
Financials (LTM)
EV
$278M
Asterasys Financials
Asterasys reported last 12-month revenue of $29M and EBITDA of $10M.
In the same LTM period, Asterasys generated $23M in gross profit, $10M in EBITDA, and $7M in net income.
Revenue (LTM)
Asterasys P&L
In the most recent fiscal year, Asterasys reported revenue of $26M and EBITDA of $9M.
Asterasys expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $29M | XXX | $26M | XXX | XXX | XXX |
| Gross Profit | $23M | XXX | $20M | XXX | XXX | XXX |
| Gross Margin | 79% | XXX | 79% | XXX | XXX | XXX |
| EBITDA | $10M | XXX | $9M | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 33% | XXX | XXX | XXX |
| EBIT Margin | 30% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $7M | XXX | $6M | XXX | XXX | XXX |
| Net Margin | 25% | XXX | 24% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Asterasys Stock Performance
Asterasys has current market cap of $294M, and enterprise value of $278M.
Market Cap Evolution
Asterasys' stock price is $7.85.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $278M | $294M | 0.0% | XXX | XXX | XXX | $0.17 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAsterasys Valuation Multiples
Asterasys trades at 9.6x EV/Revenue multiple, and 28.2x EV/EBITDA.
EV / Revenue (LTM)
Asterasys Financial Valuation Multiples
As of April 20, 2026, Asterasys has market cap of $294M and EV of $278M.
Equity research analysts estimate Asterasys' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Asterasys has a P/E ratio of 40.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $294M | XXX | $294M | XXX | XXX | XXX |
| EV (current) | $278M | XXX | $278M | XXX | XXX | XXX |
| EV/Revenue | 9.6x | XXX | 10.8x | XXX | XXX | XXX |
| EV/EBITDA | 28.2x | XXX | 32.3x | XXX | XXX | XXX |
| EV/EBIT | 31.8x | XXX | 39.3x | XXX | XXX | XXX |
| EV/Gross Profit | 12.2x | XXX | 13.6x | XXX | XXX | XXX |
| P/E | 40.0x | XXX | 46.9x | XXX | XXX | XXX |
| EV/FCF | 61.0x | XXX | 117.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Asterasys Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Asterasys Margins & Growth Rates
Asterasys' revenue in the last 12 month grew by 43%.
Asterasys' rule of 40 is 81% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Asterasys' rule of X is 148% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Asterasys Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 43% | XXX | 44% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 33% | XXX | XXX | XXX |
| EBITDA Growth | 56% | XXX | 60% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 81% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 148% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 27% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Asterasys Public Comps
See public comps and valuation multiples for other IoT and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Asterasys | XXX | XXX | XXX | XXX | XXX | XXX |
| Carlsmed | XXX | XXX | XXX | XXX | XXX | XXX |
| CapsoVision | XXX | XXX | XXX | XXX | XXX | XXX |
| TriSalus Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Soracom | XXX | XXX | XXX | XXX | XXX | XXX |
| Eurobio Scientific | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Asterasys M&A Activity
Asterasys acquired XXX companies to date.
Last acquisition by Asterasys was on XXXXXXXX, XXXXX. Asterasys acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Asterasys
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAsterasys Investment Activity
Asterasys invested in XXX companies to date.
Asterasys made its latest investment on XXXXXXXX, XXXXX. Asterasys invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Asterasys
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Asterasys
| When was Asterasys founded? | Asterasys was founded in 2015. |
| Where is Asterasys headquartered? | Asterasys is headquartered in South Korea. |
| Is Asterasys publicly listed? | Yes, Asterasys is a public company listed on Korea Exchange. |
| What is the stock symbol of Asterasys? | Asterasys trades under 450950 ticker. |
| When did Asterasys go public? | Asterasys went public in 2025. |
| Who are competitors of Asterasys? | Asterasys main competitors are Carlsmed, CapsoVision, TriSalus Life Sciences, Soracom. |
| What is the current market cap of Asterasys? | Asterasys' current market cap is $294M. |
| What is the current revenue of Asterasys? | Asterasys' last 12 months revenue is $29M. |
| What is the current revenue growth of Asterasys? | Asterasys revenue growth (NTM/LTM) is 43%. |
| What is the current EV/Revenue multiple of Asterasys? | Current revenue multiple of Asterasys is 9.6x. |
| Is Asterasys profitable? | Yes, Asterasys is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Asterasys? | Asterasys' last 12 months EBITDA is $10M. |
| What is Asterasys' EBITDA margin? | Asterasys' last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Asterasys? | Current EBITDA multiple of Asterasys is 28.2x. |
| What is the current FCF of Asterasys? | Asterasys' last 12 months FCF is $5M. |
| What is Asterasys' FCF margin? | Asterasys' last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Asterasys? | Current FCF multiple of Asterasys is 61.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.